Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study
- 1Department of Laboratory Medicine National Cancer Center Hospital Tokyo Japan
- 2Real World Evidence, Japan Access & Value, Pfizer Japan Inc. Tokyo Japan
- 3ONC Medical Affairs, Pfizer Japan Inc. Tokyo Japan
Abstract
Comprehensive genomic profiling (CGP) is standard for advanced solid tumors. Evidence reporting its real‐world utilization pattern and time course for guided therapy is limited. This retrospective study in Japan assessed the real‐world utility of CGP tests for advanced or metastatic solid tumors using data from the C‐CAT registry from June 1, 2019, to August 23, 2025. We evaluated the proportion of patients who received genomically matched therapy with expert panel (EP) recommendation and their overall survival (OS) compared with patients who did not receive genomically matched therapy. The study population comprised 89,552 patients who underwent CGP: median age 64.0 (interquartile range: 54.0–72.0) years, with pancreatic cancer (13,827; 15.4%) and colorectal cancer (11,322; 12.6%) the most common tumor types. System‐generated matched treatment options presented as reference information during EP review were identified in 80,185, of whom 77,337 (96.4%) received EP review, 37,245 (46.4%) were offered new therapeutic recommendations, and 7124 (8.9%) initiated EP‐recommended therapies. Among 2049 patients who were newly identified with companion diagnostic (CDx)‐related druggable alterations, 319 (15.6%) received matched therapies. Patients receiving matched therapies experienced longer OS compared with others in the overall cohort (median: 538 days vs. 356 days) and across cancer types. OS varied by the final treatment line before CGP testing, with earlier lines associated with longer survival in biliary tract, ovarian, pancreatic, and thyroid cancers. These findings highlight the need for timely CGP implementation to maximize the impact of precision oncology.
Trial Registration: Japan Registry of Clinical Trials identifier: jRCT1030250365
Related
- Skin‐Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real‐World Database Study (A Retrospective Cohort Study)
- Paired Tissue and Plasma Comprehensive Genomic Profiling in Advanced Solid Tumors: A Retrospective Study from India.
- Incidence and predictors of acute decompensation in adult patients with cirrhosis: a retrospective cohort study at the University of Gondar comprehensive Specialized Hospitals, Northwest Ethiopia, 2025
- Association between prognostic nutritional index and mortality in older Japanese patients with severe post-stroke dysphagia requiring nutritional support: a retrospective cohort study
- Comparative safety of imeglimin versus sitagliptin in Japanese patients with type 2 diabetes: A pharmacy-based retrospective cohort study
BibTeX
@article{sunami2026landscape,
title = {{Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study}},
author = {Kuniko Sunami and Masashi Mikami and Masayuki Tanaka and Sona‐Sanae Aoyagi and Kanae Togo},
journal = {Cancer Science},
year = {2026},
month = nov,
doi = {10.1111/cas.70561},
url = {https://doi.org/10.1111/cas.70561},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study
AU - Kuniko Sunami
AU - Masashi Mikami
AU - Masayuki Tanaka
AU - Sona‐Sanae Aoyagi
AU - Kanae Togo
PY - 2026
DA - 2026/11/03
JO - Cancer Science
DO - 10.1111/cas.70561
UR - https://doi.org/10.1111/cas.70561
AB - Comprehensive genomic profiling (CGP) is standard for advanced solid tumors. Evidence reporting its real‐world utilization pattern and time course for guided therapy is limited. This retrospective study in Japan assessed the real‐world utility of CGP tests for advanced or metastatic solid tumors using data from the C‐CAT registry from June 1, 2019, to August 23, 2025. We evaluated the proportion of patients who received genomically matched therapy with expert panel (EP) recommendation and their overall survival (OS) compared with patients who did not receive genomically matched therapy. The study population comprised 89,552 patients who underwent CGP: median age 64.0 (interquartile range: 54.0–72.0) years, with pancreatic cancer (13,827; 15.4%) and colorectal cancer (11,322; 12.6%) the most common tumor types. System‐generated matched treatment options presented as reference information during EP review were identified in 80,185, of whom 77,337 (96.4%) received EP review, 37,245 (46.4%) were offered new therapeutic recommendations, and 7124 (8.9%) initiated EP‐recommended therapies. Among 2049 patients who were newly identified with companion diagnostic (CDx)‐related druggable alterations, 319 (15.6%) received matched therapies. Patients receiving matched therapies experienced longer OS compared with others in the overall cohort (median: 538 days vs. 356 days) and across cancer types. OS varied by the final treatment line before CGP testing, with earlier lines associated with longer survival in biliary tract, ovarian, pancreatic, and thyroid cancers. These findings highlight the need for timely CGP implementation to maximize the impact of precision oncology. Trial Registration: Japan Registry of Clinical Trials identifier: jRCT1030250365
SN - 1347-9032
SN - 1349-7006
ER -